Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the authors compared topical diphencyprone and tretinoin gel for treating alopecia totalis and universalis, but the abstract does not report any definitive clinical results.

This study observed that 6.7% of patients treated with diphencyprone for alopecia areata developed vitiligo, with varying patterns and improvements noted among cases.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

In this case report, a 9-year-old boy with diffuse alopecia areata showed improvement with topical diphencyprone immunotherapy, suggesting it as a safe and effective treatment option in pediatric cases of alopecia areata resistant to other therapies.

This review discusses the use of contact sensitizers for topical immunotherapy in dermatological conditions such as alopecia areata and viral warts, but it reports no new clinical findings.

This review discusses the use of contact sensitizers in topical immunotherapy for conditions like alopecia areata and viral warts, focusing on treatment methods, efficacy, and potential adverse effects, and reports no new clinical results.

Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

In this report, a 46-year-old woman's sudden diffuse hair loss was diagnosed as granulomatous alopecia areata, with spontaneous hair regrowth observed after two months. This case highlights that granulomatous inflammation should not exclude the diagnosis of alopecia areata, emphasizing the importance of clinicopathological correlation.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.

This study found that mechlorethamine restored hair growth in mice with alopecia-areata-like disease by eliminating infiltrated lymphocytes and inhibiting certain pro-inflammatory cytokines in treated skin areas.

This study found that topical melatonin and vigorous brushing did not affect hair regrowth in clipped Siberian Huskies, although lumbosacral hairs grew significantly shorter than lateral thigh hairs.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

This study found that Betamethasone was more effective than Tacrolimus and soft paraffin in promoting hair regrowth in patients with mild to moderate patchy alopecia areata.

Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.

This research reported that squarticles, nanoparticles made from sebum-derived lipids, enhanced the follicular delivery and skin accumulation of diphencyprone and minoxidil, indicating effective drug deposition with reduced systemic absorption in alopecia treatment.

This study found that dutasteride-loaded nanostructured lipid carriers coated with a stearic acid-chitosan oligomer are stable, less cytotoxic, and suitable for topical delivery to promote hair growth.

This study found that adapalene-loaded solid lipid microparticles may enhance targeted drug delivery into sebum due to their similarity to sebum components, although both this formulation and a standard cream showed equivalent follicular penetration.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.

In this retrospective study, anti-tuberculous agents, likely rifampicin, were effective adjunctive therapies for a chalazion, coinciding with spontaneous drainage in a patient with rosacea.